Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
This is a research compound with no FDA-approved use
It begins below the obesity-trial floor because appetite and gastrointestinal effects need time to adapt before escalation. At 5 mg, both GIP and GLP-1 are clinically active
Target pathway semaglutide/tirzepatide: gut-brain axis, insulin secretion, appetite
Triglycerides synthesized in the liver are packaged into VLDL and released into the blood directly
A lot/batch identifier is recorded on the product label where available and corresponds to the COA shown on this page
Staying informed through reputable sources such as the NHS website , NICE (nice.org.uk), and the MHRA (gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency) will help you make safe and well-informed decisions about your care
